Empowering Patients Through Innovative Solutions in Cancer Care
At Curadel Pharma, the fight against cancer is being redefined through groundbreaking scientific developments designed to transform how we detect, diagnose, and treat cancer.
FDA and EMA Grant Orphan Drug Designation for Curadel’s CPI-008, a Targeted Zwitterionic Imaging Drug for Pancreatic Cancer
US and EU regulatory designations provide critical development resources to advance novel tumor detection technology
Curadel Pharma Initiates Phase 3 Trial of ZW800-1, a First-in-class Zwitterionic Drug for Optical Surgical Navigation
Curadel Pharma, a pioneer in zwitterionicity and innovator in advanced radiotherapies and drugs for optical surgical navigation, announced today that it has initiated the Phase 3 portion of its pivotal study evaluating the investigational ZW800-1 (nizaracianine triflutate) to highlight the ureter during abdominopelvic surgery.
Curadel Pharma secures $10.5M in series A2 funding to propel novel Zwitterionic Radiotherapy Platform
Curadel Pharma, a pioneer in zwitterionicity and innovator in advanced radiotherapies and imaging drugs, announced completion of a Series A2 funding round, securing $10.5M to advance early stage development for its lead programs.
Curadel Pharma initiates Phase 2 Portion of the Pivotal trial of ZW800-1, a first-in-class Zwitterionic Ureter imaging surgical drug
Curadel Pharma, a pioneer in zwitterionicity and innovator in advanced radiotherapies and imaging drugs, announced the initiation of a pivotal study evaluating its investigational imaging-guided drug ZW800-1 (nizaracianine triflutate) to highlight the ureter during abdominopelvic surgery.